Gland Pharma receives approval for Latanoprost Opthalmic Solution, 0.005%
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
The product will be marketed by Dr. Reddy's
GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Subscribe To Our Newsletter & Stay Updated